CLCA2 Interactor EVA1 Is Required for Mammary Epithelial Cell Differentiation.

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• Chloride channel CLCA2 is a transmembrane protein downregulated in breast cancer, and its loss induces epithelial-to-mesenchymal transition (EMT).
• Epithelial V-like Antigen 1 (EVA1) is a cell junction protein also regulated by p53/p63 and implicated in epithelial differentiation.
• Both CLCA2 and EVA1 are frequently downregulated in breast tumors, particularly in those with mesenchymal characteristics.

Purpose of the Study:

• To investigate the molecular mechanisms by which CLCA2 promotes epithelial differentiation.
• To identify CLCA2 interacting partners involved in maintaining epithelial characteristics.

Main Methods:

• Membrane yeast dihybrid screening to identify CLCA2 interactors.
• Co-immunoprecipitation to confirm protein-protein interactions.
• Deletion analysis to map interaction domains.
• Knockdown and overexpression studies in human mammary epithelial cells (HMECs).

Main Results:

• CLCA2 strongly interacts with the cell junction protein EVA1 via their transmembrane segments.
• EVA1 knockdown in HMECs induces EMT, highlighting its essential role in epithelial differentiation.
• CLCA2 and EVA1 co-localize with E-cadherin at cell-cell junctions.
• CLCA2 also interacts with ZO-1 and beta-catenin, and its overexpression downregulates beta-catenin signaling.

Conclusions:

• CLCA2 and EVA1 are critical for maintaining mammary epithelial cell adhesion and differentiation.
• The interaction between CLCA2 and EVA1, conserved across mammals, likely co-evolved with the mammary gland.
• CLCA2's role in linking cell adhesion to beta-catenin signaling explains its tumor-suppressive function and downregulation in metastatic breast cancer.